ARTICLE | Deals
After stumbles along winding path, Acelyrin merges with Alumis: Deals Report
Plus: Pair of cash-rich biotechs agree to combine, and Australian radiopharma company Advancell follows venture round by expanding Lilly relationship
February 11, 2025 1:10 AM UTC
A merger with Alumis will spell the end of Acelyrin’s five-year run as an independent company, mostly leaving disappointment in its wake as its first in-licensed program ended up being a bust.
Launched in 2020, Acelryin Inc. (NASDAQ:SLRN) was conceived as a venture-backed bet on experienced drug-hunters who intended to in-license the best available immunology assets and move them forward. Hopes ran high for the first molecules it chose, allowing the biotech to complete a $621 million IPO, the sector’s biggest of 2023...